See http://www.wildeaboutsteroids.co.uk/
The site does not sell anything and has no banners or sponsors or adverts - just helpful information.
New evidence linking the use of acetaminophen to development of asthma and eczema suggests that even monthly use of the drug in adolescents may more than double risk of asthma in adolescents compared to those who used none at all; yearly use was associated with a 50 percent increase in the risk of asthma.
Read article at physorg.com
Comment by Dr Rath Foundation: Based upon research involving more than 300,000 13- and 14 year old children in 113 centers throughout 50 countries, the results of this study follow hot on the heels of independent research that links acetaminophen (Paracetamol) not only to asthma but also to hearing loss and adverse vision events. As such, as the leading cause of liver failure in the United States and carrying a much increased risk of stroke and heart attack, it is becoming increasingly clear that the dangers of acetaminophen are far higher, and more numerous, than the business with disease and its friends in the drug regulatory agencies would have you believe.
The US Department of Justice is scrutinising payments by leading pharmaceuticals companies for hospitality, consultants, licensing agreements and charitable donations in markets around the world as part of a wide-ranging corruption probe. GlaxoSmithKline, Pfizer, Bristol-Myers Squibb and Eli Lilly, among others, have disclosed being contacted by the DoJ and Securities and Exchange Commission in connection with the investigation. Merck, the US drugs group, announced that it had also been contacted and was co-operating with investigators.
Read article at yahoo.com
An investigation is long overdue, surely?
AstraZeneca is moving closer to resolving the large number of lawsuits filed in the US over claims that the risks of its Seroquel antipsychotic were not properly disclosed. In this disclosure, AstraZeneca has agreed to pay about $198 million to settle 17,500, or roughly two-thirds of the outstanding lawsuits, according to a statement.
Read article at pharmalot.com
"Individual benefit from mammography is thus very small, but this is not widely understood. In part this is due to obfuscation from organisers of mammography services assuming that a positive emphasis is needed to ensure reasonable compliance," Professor McPherson says.
He calls for a "full examination of all the data" and more honesty from the NHS about the scientific uncertainties. He also suggests that the National Institute for Clinical Excellence (NICE) should review the evidence.
"There is no doubt that screening for breast cancer has limited benefit and some possibility of harm for an individual woman and is of marginal cost-effectiveness for the community... The NHS screening programme needs to be really clear about the uncertainties when communicating with women... More importantly we all need to understand better how a national programme of such importance could exist for so long with so many unanswered questions.""
I have always considered routine mammography screening as an expensive political pretence of concern for women's health, that actually does far more harm than good to the women screened. Screening is not prevention, though it seems to be promoted as though it is prevention. Prevention should be the primary aim where cancer is concerned, but the Cancer Research industry accords little effort to prevention.